TrialBlood2015
Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS.
Roxanne Cofiell et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
108 papers cite itlatest 60 shown
this paperpooled ittrialcites it